ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "complement"

  • Abstract Number: 1733 • ACR Convergence 2022

    Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium

    Anna Jonsson1, Carlos Donado2, Emma Gomez-Rivas1 and Michael Brenner3, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. Most research has focused on CD4 T cells, but we have found that CD8+…
  • Abstract Number: 2096 • ACR Convergence 2022

    Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus

    Marcela Muñoz Urbano1, Diana C. Quintero-González1, Mauricio Rojas2, Joaquín Rodelo1, Alba Luz León Álvarez1, Luis Gonzalez1 and Gloria Vásquez3, 1Universidad de Antioquia, Medellín, Colombia, 2Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, 3Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia

    Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
  • Abstract Number: 0144 • ACR Convergence 2022

    The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease

    Guy Katz1, Amelia S. Cogan1, Grace McMahon1, Sebastian Perez-Espina1, Ana Fernandes1, Cory Perugino1, Zachary Wallace1, John Atkinson2, Alfred Kim2 and John Stone3, 1Massachusetts General Hospital, Boston, MA, 2Washington University School of Medicine, St. Louis, MO, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with…
  • Abstract Number: 0317 • ACR Convergence 2022

    Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression

    Ivan Ferraz Amaro1, maría García-González2, carmen Ferrer-Moure2, Fuensanta Gómez-Bernal2, Antonia De Vera-González2, Alejandra González Delgado2, Agustín Francisco González-Rivero2, Yolanda Fernández-Cladera2, Juan Carlos Quevedo Abeledo3 and Federico Díaz-González4, 1Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 3Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife

    Background/Purpose: Activation of the classical complement (C) pathway by immune complexes is a characteristic of patients with systemic lupus erythematosus (SLE). Accelerated consumption outstrips synthesis…
  • Abstract Number: 0524 • ACR Convergence 2022

    A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis

    Peter Merkel1, Bernhard Hellmich2, Anja Pfaff3, Carina Müller4, Elena Startseva3 and David Jayne5, 1University of Pennsylvania, Philadelphia, PA, 2Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 3InflaRx, Jena, Germany, 4Metronomia Clinical Research, Munich, Germany, 5University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Induction of remission for severe ANCA-associated vasculitis [granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)] utilizes rituximab (RTX) or cyclophosphamide (CYC) and tapering doses…
  • Abstract Number: 0565 • ACR Convergence 2022

    Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissues Using Single-cell Computational Omics

    Juan Vargas1, Nirmal Banda2, Ian Mantel3, Anna Jonsson4, Kevin Wei5, Deepak Rao4, Susan Goodman6, Kevin D Deane7, Jennifer Seifert8, Jennifer Anolik9, Michael Brenner10, Soumya Raychaudhuri4, Accelerating Medicines Partnership RA/SLE4, Michael Holers2, Laura Donlin6 and Fan Zhang8, 1School Public Health Biostatistics Department, Aurora, CO, 2Department of Medicine Division of Rheumatology, Aurora, CO, 3Weill Cornell Medicine, New York, NY, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Hospital for Special Surgery, New York, NY, 7University of Colorado Denver Anschutz Medical Campus, Denver, CO, 8University of Colorado, Aurora, CO, 9University of Rochester Medical Center, Rochester, NY, 10Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune arthritis pathogenesis. In patients…
  • Abstract Number: 0648 • ACR Convergence 2022

    Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients

    Edmund Chang1, Julian Low2, Ellen Cahir-McFarland2, Henk-Andre Kroon2, Yaisa Andrews-Zwilling2, Ted Yednock2 and Ann Mongan2, 1Annexon Biosciences, Brisbane, CA, 2Annexon Biosciences, South San Francisco, CA

    Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…
  • Abstract Number: 0650 • ACR Convergence 2022

    The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis

    Shudan Wang1, Masako Suzuki2, Daming Shao3, Muhammad Hamza Bukhari4, Brianna Lally5, Michael Belmont6, Jennifer Aguilan2, Simone Sidoli2, Anna Broder7 and J. Michelle Kahlenberg8, 1Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 4Norwalk Hospital/Yale University, Norkwalk, VA, 5University of Wisconsin Hospitals and Clinics, Madison, WI, 6NYU Grossman School of Medicine, New York, NY, 7Hackensack University Medical Center, Hackensack, NJ, 8University of Michigan, Ann Arbor, MI

    Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…
  • Abstract Number: 0692 • ACR Convergence 2022

    The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis

    Naveen Kumar S K1, Claire Hoy1, Christine Rysenga1, Srilakshmi Yalavarthi1, Cyrus Sarosh2, Sherwin Navaz1, Jacqueline Madison1, Jason S Knight3 and Yu (Ray) Zuo1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Temperance, MI, 3University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Lipid peroxidation is the result of disrupted redox homeostasis and functions as a key component in various cell death programs. Neutrophil extracellular trap (NET)…
  • Abstract Number: L14 • ACR Convergence 2021

    Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis

    David Jayne1, Peter Merkel2, Annette Bruchfeld3, Duvuru Geetha4, Alexandre Karras5, John Niles6 and Pirow Bekker7, 1University of Cambridge, Cambridge, United Kingdom, 2University of Pennsylvania, Philadelphia, PA, 3Linköping University, Linköping, Sweden, 4Johns Hopkins University, Baltimore, MD, 5Hopital Europeen Georges Pompidou, Paris, France, 6Massachusetts General Hospital, Boston, MA, 7ChemoCentryx, Inc., San Carlos, CA

    Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
  • Abstract Number: 0423 • ACR Convergence 2021

    Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis

    Salem Almaani1, Huijuan Song2, Meshora Sthanithra2, Christopher Toy2, Anna Levesque2, Lynn Fussner3, Alexa Meara3, Haikady Nagaraja2, David Cuthbertson4, Nader Khalidi5, CURRY LEE MD KOENING6, Carol Langford7, Carol McAlear8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Antoine Sreih12, Kenneth Warrington13, Paul Monach14, Peter Merkel8, Brad Rovin3 and Dan Birmingham2, 1Ohio State University Medical Center, Columbus, OH, 2Ohio State university, Columbus, OH, 3Ohio State University Wexner Medical Center, Columbus, OH, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, 7Cleveland Clinic, Moreland Hills, OH, 8University of Pennsylvania, Philadelphia, PA, 9University of Colorado, Denver, CO, 10Mount Sinai Hospital, Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Univeristy of Pennsylvania, Philadelphia, PA, 13Mayo Clinic, Rochester, Minnesota, 14Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…
  • Abstract Number: 0873 • ACR Convergence 2021

    Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study

    Marcela Muñoz-Urbano1, Julian Sanchez-Bautista2, Yeison Santamaria-Alza1, Diana C. Quintero-González3, Andres Ramirez2, Adriana Lucía Vanegas-García4, Gloria M. Vasquez1 and Luis Alonso Gonzalez3, 1Rheumatology section, Universidad de Antioquia, Medellín, Colombia, 2Department of internal medicine, Universidad de Antioquia, Medellín, Colombia, 3Division of rheumatology, Universidad de Antioquia, Medellín, Colombia, 4Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia

    Background/Purpose: Lupus enteritis (LE) is a potentially life-threatening manifestation of systemic lupus erythematosus (SLE), with an incidence ranging from 8% to 27%. Timely diagnosis is…
  • Abstract Number: 0955 • ACR Convergence 2021

    The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis

    Vibeke Strand1, Pirow Bekker2, Huibin Yue2, David R.W. Jayne3 and Peter Merkel4, 1Stanford University School of Medicine, Portola Valley, CA, 2ChemoCentryx, San Carlos, CA, 3University of Cambridge, Cambridge, United Kingdom, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was evaluated in ANCA-associated vasculitis (AAV). Efficacy and safety results were reported previously. Health-related quality of life (HRQoL)…
  • Abstract Number: 1086 • ACR Convergence 2021

    Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers

    Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA

    Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
  • Abstract Number: 1370 • ACR Convergence 2021

    Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)

    Roberta G Marangoni1, Changyong Feng1, Ashley Frazer-Abel2, Stephen Tomlinson3, Amy Wielgosz1, Katie Lutz4, Michael Pauciulo4, William Nichols4, V. Michael Holers5, Christopher Ritchlin6, R James White III1 and Benjamin Korman1, 1University of Rochester, Rochester, NY, 2University of Colorado Denver, Colorado, CO, 3Medical University of South Carolina, Charleston, SC, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5University of Colorado, Denver, CO, 6Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology